Camidge, D. Ross
Doebele, Robert C.
Kerr, Keith M.
Article History
First Online: 4 February 2019
Competing interests
: D.R.C. has ad hoc advisory roles with ARIAD, Arrys/Kyn, AstraZeneca, Bio-Thera DSMB, Celgene, Clovis, Daiichi Sankyo (interstitial lung disease adjudication committee), G1 Therapeutics (DSMB), Genoptix, Hansoh SRC, Hengrui, Ignyta, Lycera, Mersana Therapeutics, Novartis, Orion, Regeneron, Revolution Med, Roche/Genentech and Takeda and has received research funding from Takeda. R.C.D. is an advisory board member for ARIAD, AstraZeneca, Ignyta, Spectrum and Takeda; has received research sponsorship from Ignyta and licensing fees from Abbott Molecular, Ignyta and Rain Therapeutics; and owns stock in Rain Therapeutics. K.M.K. has been a consultant for and has received speaker’s honoraria from AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, Merck Serono, Merck Sharp and Dohme, Novartis, Pfizer, Roche and Ventana and has been a consultant for AbbVie.